Wednesday, July 01, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
We Now Expect Product Approval Around YE2026. Unicycive announced it has received a CRL (Complete Response Letter) stating that the NDA for OLC (oxylanthanum carbonate), its phosphate binder for patients on dialysis, has not been approved. The reason stated is that the FDA has not conducted its required inspection of the third-party manufacturing vendor. This step is expected to be completed during the summer, allowing for an NDA resubmission and approval near YE2026.
All Other Steps In The NDA Review Appear To Be Complete. The FDA inspection appears to have been the only remaining step for OLC approval. After a meeting with the FDA, steps to resolve manufacturing issues with the third-party vendor were identified, addressed, and the plant readied for inspection. The review of clinical efficacy and safety data was completed in 2025, with no new issues raised. Product labeling and packaging discussions have been ongoing, typically the last step before approval.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
